Zika Virus-Like Particles - Vaccine Lab / Alfa Chemistry

Product Overview

Zika Virus-Like Particles (VLPs) are recombinant, self-assembled particles composed of the key structural proteins of Zika virus, including Envelope (E), pre-Membrane (prM), and Membrane (M). Produced in human HEK293 cells, these VLPs closely mimic the morphology and antigenic properties of native virions while remaining non-infectious due to the absence of viral genetic material.

This product is developed to support vaccine research, immunogen design, and diagnostic assay development. The use of a mammalian expression system ensures proper protein folding and native-like post-translational modifications, including glycosylation, enabling biologically relevant antigen presentation.

Key Features

Native-Like Structure: Accurately mimics the conformation of authentic Zika virus particles

High Purity: ≥95% purity confirmed by SDS-PAGE

Mammalian Expression System: Ensures correct folding and post-translational modifications

Non-Infectious: Free of viral genome for safe laboratory handling

R&D-Ready: Suitable for vaccine development, antibody generation, and assay development

Technical Specifications

Item	Specification
Product Name	Zika Virus-Like Particles
Catalog Number	ACVL-VLP009
Expression System	HEK293 Mammalian Cells
Protein Components	Envelope (E), pre-Membrane (prM), Membrane (M)
Purity	≥95% (SDS-PAGE)
Formulation	DPBS, pH 7.4
Appearance	Clear to slightly opalescent solution
Storage	-80 °C recommended

Applications

Vaccine candidate evaluation and immunogen design
Development of serological assays (e.g., ELISA, neutralization assays)
Antibody discovery and validation
Structural and antigenicity studies

Background

Zika virus is a mosquito-borne flavivirus transmitted primarily by Aedes species. Since its emergence as a global health concern, particularly during outbreaks in the Americas, it has been associated with neurological complications and congenital abnormalities.

The development of safe and effective countermeasures remains a priority. Virus-like particle technology has gained significant attention as a next-generation vaccine platform due to its ability to present viral antigens in a highly immunogenic and structurally relevant format without the risks associated with live or attenuated viruses.

Why Choose This Product

Consistent quality with reliable batch-to-batch reproducibility

High structural fidelity to native viral particles

Suitable for a wide range of immunological and analytical applications

Manufactured under rigorous quality control standards

Our products and services are for research use only and cannot be used for any clinical purposes.

Online Inquiry